Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response?
Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.
Department of Pathology and Anatomical Sciences, Ellis Fischel Cancer Center, University of Missouri School of Medicine, Columbia, Missouri 65203, USA.
Susan H
SH
Wei
Robert
R
Brown
Tim H-M
TH
Huang
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015139:Blotting, Southern; D018899:CpG Islands / Q000235:genetics; D019175:DNA Methylation; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents